Riskpilot← Back to searchSign inGet full accessTRONDHEIM LUNGELEGESENTER AS
ASActiveOrg 992272139Kjøpmannsgata 31, 7011 TrondheimMedical specialists activities · NACE 8622Est. 20083 employees
Revenue 2024
NOK 8,1M
-2% vs 2023
EBITDA margin
9.0%
-16% vs 2023
Equity ratio
19.1%
Financial strength
Net profit 2024
NOK 542K
-18% vs 2023
| Revenue | NOK 8,1M | -2% |
| EBITDA | NOK 728K | -16% |
| Net profit | NOK 542K | -18% |
| Total assets | NOK 1,7M | -28% |
| Equity | NOK 327K | -60% |
| Employees | 3 | — |
Legal name
TRONDHEIM LUNGELEGESENTER AS
Org number
992272139
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
4. februar 2008
Share capital
NOK 30 000
Employees
3 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Spesialistlegepraksis i indremedisin og lungesykdommer, flylege samt kurs, forskning og undervisning.
Address
Kjøpmannsgata 31, 7011 Trondheim
Phone
+4773520530
Email
alf.magne.heggli@lungelegesenter.nhn.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 6 532 | 6 916 | 7 387 | 8 201 | 8 073 |
| Staff expenses | −4 232 | −4 205 | −4 383 | −4 974 | −5 084 |
| EBITDA | 422 | 674 | 1 035 | 871 | 728 |
| Depreciation & amort. | −222 | −187 | −33 | −30 | −35 |
| EBIT | 200 | 487 | 1 002 | 841 | 693 |
| Net financials | 1 | 6 | 1 | 4 | 2 |
| Profit before tax | 199 | 493 | 1 003 | 844 | 695 |
| Tax | 44 | 109 | 221 | 186 | 153 |
| Net profit | 155 | 385 | 782 | 659 | 542 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 096 | 2 012 | 2 521 | 2 356 | 1 707 |
| Equity | 721 | 586 | 1 010 | 818 | 327 |
| Long-term debt | 248 | 185 | 0 | 29 | 25 |
| Short-term debt | 1 127 | 1 242 | 1 511 | 1 509 | 1 355 |
| Total debt | 1 375 | 1 426 | 1 511 | 1 538 | 1 380 |
EBITDA margin
9.0%
This company
15.8%
Market median
-43% vs market
20202024
Equity ratio
19.1%
This company
38.2%
Market median
-50% vs market
20202024
Return on equity
166.0%
This company
18.4%
Market median
+802% vs market
20202024
Net profit margin
6.7%
This company
8.1%
Market median
-17% vs market
20202024
Asset turnover
4.73×
This company
1.12×
Market median
+322% vs market
20202024
Debt / equity
4.23×
This company
0.62×
Market median
-582% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
WI Deputy Member | Deputy Member | 2008 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2008 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Heggli Invest As
TRONDHEIM LUNGELEGESENTER AS Board members of TRONDHEIM LUNGELEGESENTER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Wenche Irene Staberg Heggli | Deputy Member | 0 companies |
| Alf Magne Heggli | Chairman | 0 companies |